title: Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody.
abstract: BACKGROUND
  Lymph node lymphocytes vary in their responsiveness to tumor. A technique has been developed that uses radiolabeled monoclonal antibody (MoAb) against the tumor-associated mucin, TAG-72, and a gamma-detecting probe by which lymph nodes containing microscopic tumor and/or shed TAG-72 can be identified in vivo. The immunologic characteristics of these lymph nodes were examined.
  
  
  METHODS
  Patients with colon cancer received 125I-labeled MoAb CC49 by intravenous injection preoperatively. During laparotomy lymph nodes that appeared normal on inspection and palpation but which contained radiolabeled MoAb were identified using a hand-held gamma-detecting probe. These lymph nodes and other lymph node and tumor specimens were resected for analysis.
  
  
  RESULTS
  Lymph nodes identified by the probe were found by immunohistochemical studies to contain microscopic tumor and/or shed antigen associated with germinal centers. They were characterized by greater CD4+:CD8+ ratios, rates of expansion, and cytolytic activity compared with lymphocytes from lymph nodes with macroscopic tumor, noninvolved lymph nodes, and tumors. All lymph node lymphocytes identified by the probe demonstrated significant proliferative responses to autologous tumor and, in contrast to lymphocytes from noninvolved lymph nodes, significant proliferative responses to allogeneic TAG-72+ tumor cells and to soluble TAG-72+ mucin.
  
  
  CONCLUSIONS
  By locating lymph nodes with microscopic tumor and/or shed antigen, the use of radiolabeled MoAb in vivo can be used to reproducibly identify tumor-reactive lymph node lymphocytes. This technique may be useful in identifying cells for use in adoptive immunotherapy programs and in studying the regulation of immune responses in vivo.
authors.affiliation: Department of Medicine, Ohio State University Comprehensive Cancer Center/Arthur G. James Cancer Hospital and Research Institute, Columbus.
authors.forename: P L
authors.initials: PL
authors.lastname: Triozzi
authors.forename: J A
authors.initials: JA
authors.lastname: Kim
authors.forename: W
authors.initials: W
authors.lastname: Aldrich
authors.forename: D C
authors.initials: DC
authors.lastname: Young
authors.forename: J W
authors.initials: JW
authors.lastname: Sampsel
authors.forename: E W
authors.initials: EW
authors.lastname: Martin
mesh_terms: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology; D016516:CD4-CD8 Ratio; D003110:Colonic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007457:Iodine Radioisotopes; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology*; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006023:Glycoproteins; D007457:Iodine Radioisotopes; C047052:tumor-associated antigen 72